Free press releases distribution network?

Agency / Source: Comago

Check Ads Availability|e-mail Article


Are you the owner of this article?, Turn it PREMIUM with your LOGO instead - and make it 3rd party Ads-Free! within the next hour!



OrganoBalance Signs Licensing Agreement with Sanofi Pasteur - Modified strain of yeast paves way for new industrial vaccine production process - OrganoBalance.com
OrganoBalance Signs Licensing Agreement with Sanofi Pasteur

 

PRZOOM - /newswire/ - Falkensee, Brandenburg, Germany, 2012/01/11 - Modified strain of yeast paves way for new industrial vaccine production process - OrganoBalance.com.

   
 
Your Banner Ad Here instead - Showing along with ALL Articles covering Pharma/BioTech/Nutrition Announcements

Replace these Affiliate Programs at ANYTIME! Your banner here within the next hour. Learn How!


 

The company ORGANOBALANCE GmbH, Berlin, Germany, today announced the conclusion of a licensing agreement with Sanofi Pasteur, the vaccines division of Sanofi (EURONEXT: SAN and NYSE: SNY). This will provide Sanofi Pasteur with access to a modified yeast strain (Saccharomyces cerevisiae, more commonly known as baker's yeast) for use in vaccines. By signing the agreement, ORGANOBALANCE is granting Sanofi Pasteur exclusive rights to use of the modified yeast strain in the production of vaccines.

Prof. Christine Lang, Managing Director of ORGANOBALANCE GmbH, sees the licensing agreement as a further milestone for the company: "The modified form of Saccharomyces cerevisiae, both developed and patented by our company, is just one example of the far-reaching expertise ORGANOBALANCE has to offer in the field of metabolic engineering. By making this agreement, we are strengthening our outstanding position in microbial strain development and the application of yeasts in industrial biotechnology. We are delighted to have made this agreement with Sanofi Pasteur, a partner who will make commercial use of our research findings on an industrial scale."

About ORGANOBALANCE

ORGANOBALANCE GmbH (organobalance.com) is a company specialising in microbiological strain development. ORGANOBALANCE targets the use of Saccharomyces cerevisiae yeast strains for synthesising materials which can be applied in the processes of industrial and pharmaceutical biotechnology. The company also focuses on tapping the potential of beneficial microorganisms, known as specific probiotic cultures, in order to balance out the microflora and restore the microbial equilibrium in a natural way. By drawing on its own collection of microorganisms suitable for use in foodstuffs, as well as its own OASSYS® screening systems, ORGANOBALANCE develops new biological products in the areas of pharmaceutics, preventive healthcare, nutrition and cosmetics. ORGANOBALANCE was founded in 2001 and is based in Berlin, Germany.

Further information:
ORGANOBALANCE GmbH
Gustav-Meyer-Allee 25 - 13355 Berlin - Germany
T: +49 30 46307-200 / F: +49 30 46307-210 - E: info[.]organobalance.com.

 
 
Your Banner Ad Here instead - Showing along with ALL Articles covering Pharma/BioTech/Nutrition Announcements

Replace these Affiliate Programs at ANYTIME! Your banner here within the next hour. Learn How!


 

Agency / Source: Comago

 
 

Availability: All Regions (Including Int'l)

 

Traffic Booster: [/] Quick PRZOOM - Press & Newswire Visibility Checker

 

Distribution / Indexing: [+]

 
 
# # #
 

 
  Your Banner Ad showing on ALL
Pharma/BioTech/Nutrition articles,
CATCH Visitors via Your Competitors Announcements!


OrganoBalance Signs Licensing Agreement with Sanofi Pasteur

Company website links NOT available to basic submissions
It is OK to republish and/or LINK any newswire for any legitimate media purpose as long as you name PRZOOM - Press & Newswire and LINK as the source.
 
  For more information, please visit:
Is this your article? Activate ALL web links by Upgrading to Press Release PREMIUM Plan Now!
|
Contact: Helmut Landenberger - Comago.de 
+49 33 22 84 06 52 landenberger[.]comago.de
 
PRZOOM / PRTODAY - Newswire Today disclaims any content contained in this article. If you need/wish to contact the company who published the current release, you will need to contact them - NOT us. Issuers of articles are solely responsible for the accuracy of their content. Our complete disclaimer appears here.
IMPORTANT INFORMATION: Issuance, publication or distribution of this press release in certain jurisdictions could be subject to restrictions. The recipient of this press release is responsible for using this press release and the information herein in accordance with the applicable rules and regulations in the particular jurisdiction. This press release does not constitute an offer or an offering to acquire or subscribe for any Comago securities in any jurisdiction including any other companies listed or named in this release.

Pharma/BioTech/Nutrition via RSSAdd NewswireToday - PRZOOM Headline News to FeedBurner
Find who RetweetFollow @NewswireTODAY



Are you the owner of this article?, Turn it PREMIUM with your LOGO instead - and make it 3rd party Ads-Free! within the next hour!




Read Latest Press Releases From Comago / Company Profile


Read Pharma/BioTech/Nutrition Most Recent Related Press Releases:

Frost & Sullivan Commends Nemaura for Developing Superior Transdermal Drug Delivery Technology Platforms, the Memspatch and Micropatch
Greenphire Sponsors Second Annual Clinical Trial Agreements, Investigator Payments and Fair Market Value Meeting
Genentech’s Gazyva Helped People with Previously Untreated Follicular Lymphoma Live Significantly Longer
BD Announces Adoption of Windows 10 ‘Internet of Things’ for the Pyxis™ ES System
Greenphire Named to Deloitte 2016 Technology Fast 500™
Genentech Showcases New Clinical Data Across a Variety of Blood Diseases at American Society of Hematology 2016 Annual Meeting
BD Collaborates with JDRF to Focus on Extended Wear Innovations for Insulin Infusion Delivery
BD Launches First Syringe Designed for Use with Humulin® R U-500 Insulin
MDxHealth Announces Unique CPT Code Awarded for ConfirmMDx from the American Medical Association
BD MAX™ Vaginal Panel Receives FDA Market Authorization to Detect Most Common Causes of Vaginal Infections

Boost Your Social Network
& Crowdfunding Campaigns


LIFETIME SOCIAL MEDIA WALL
 
NewswireToday Celebrates 10 Years in Business
Find business coaching, life coaching, executive coaching and corporate coaching, best selling coaching books, ...



PREMIUM Members


Visit  JobsWare.com

Visit  Triggr & Bloom

Visit  La Bella Bakery Artisan Bakery Arizona







 
  ©2016 PRZOOM — Limelon Advertising, Co.
Home | About PRZOOM | Advertise/Pricing | Contact | Investors | Privacy/TOS | Sitemap | FRANCAIS
newswire, PR free press releases distribution service magazines engine news alert newsroom press room breaking news public relations articles company news alerts newswiredistribution ezine bizentrepreneur biznewstoday digital business report market search pr firms agencies reports distri-bution today investor relation successful internet entrepreneur newswire distribution prtoday.com freenewswiredistribution asianewstoday bizwiretoday USA pr UK today